HeartSciences Inc. Warrant - HSCSW STOCK NEWS

HeartSciences (NASDAQ: HSCS) presented a study showcasing the effectiveness of MyoVista wavECG in screening preoperative patients for LVDD at the 18th World Congress of Anesthesiologists. The study demonstrated 100% sensitivity in detecting LVDD, potentially reducing unnecessary referrals to echocardiography. MyoVista wavECG shows promise in transforming cardiovascular medicine and is set to be commercially available soon.

HeartSciences, a medical technology company, reported Q3 FY2024 financial results showing a strengthened financial position, strategic shifts, and business highlights. Key accomplishments include acquiring AI-ECG algorithms from Mount Sinai, FDA pathway changes, and enhanced team recruitment. The company aims to lead the AI-ECG market with improved financials, extended cash runway, and clinical advancements.

HeartSciences (NASDAQ: HSCS) announces a study showing MyoVista AI-ECG model outperforms NT-proBNP and ARIC HF score in Stage B Heart Failure screening among type 2 diabetes patients. The study highlights the potential of AI-ECG technology to enhance heart disease detection and screening processes.

HeartSciences, an AI-powered medical technology company, has received a patent grant from the Canadian Intellectual Property Office for its AI-ECG technology. The company aims to revolutionize heart disease detection, reduce treatment costs, and capitalize on the growing ECG market, with a projected value of $25 billion by 2032.

HeartSciences appoints Dr. Partho P. Sengupta, a renowned cardiologist, to its Scientific Advisory Board. Dr. Sengupta brings vast experience and expertise in AI-ECG technology, enhancing HeartSciences' position in the field.

HeartSciences appoints Dr. Jordan B. Strom to its Scientific Advisory Board, enhancing expertise in AI-based medical devices and preparing for FDA submission of MyoVista device and cloud platform.

HeartSciences (HSCS) appoints Dr. Benjamin Glicksberg, an elite data scientist and lead investigator of AI algorithms licensed by the company, to its Scientific Advisory Board. The appointment follows the recent closing of agreements with Mount Sinai, covering an industry-leading portfolio of AI-based ECG/EKG algorithms, technologies, and patent rights for the screening and diagnosis of cardiovascular disease. The company aims to achieve significant milestones, including launching a hardware-agnostic cloud platform to deliver the AI-ECG algorithms licensed from Mount Sinai and obtaining FDA clearance for its MyoVista wavECG device. Dr. Glicksberg's expertise in machine learning, digital health, and bioinformatics is expected to contribute to expanding the clinical diagnostic capabilities of the ECG/EKG, transforming the early detection of heart disease.

HeartSciences (Nasdaq: HSCS; HSCSW) announced the results of the 2024 Annual Meeting of Shareholders, including the passing of important resolutions and an adjournment in respect of Proposal 7. Approximately 54.37% of the Company’s outstanding shares were represented at the meeting. The shareholders approved the re-election of director nominees, the issuance of shares of common stock, the Equity Incentive Plan, the independent registered public accounting firm, and amendments to the Company’s Certificate of Formation. Proposal 7, which aimed to lower the quorum for future meetings, was adjourned until February 15, 2024 due to insufficient votes. The reconvened Annual Meeting will be held virtually, and shareholders are encouraged to vote by February 14, 2024.

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.